Market Research Trends

The global  Antidiabetics Market  is estimated to secure US$ 223 Billion while expanding at a CAGR of 9.6% during the forecast period. The growth of the market can be attributed to the increasing prevalence of diabetes across the globe. Also, the aging baby boomer is another factor driving the market in the forecast period. According to International Diabetes Federation, the global diabetes incidence is anticipated to increase from 366 million in 2011 to 552 million by 2030. Such a significant increment in the number of diabetic patients is projected to benefit the industry in the forecast period. Also, the development of new products is anticipated to benefit the market in the coming time. For instance, in January 2022, Novo Nordisk, the Danish drug provider, announced the launch of oral semaglutide in India for the treatment of Type 2 diabetes. Moreover, the development of advanced pumps based on smart technologies such as; AI and ML are predicted to offer various opport...

The global Antidiabetics Market is expected to earn US$ 223 billion while expanding at a CAGR of 9.6% during the forecast period. The rising prevalence of diabetes worldwide can be attributed to the market's expansion. The ageing baby boomer population is another factor driving the market during the forecast period. According to the International Diabetes Federation, the global diabetes incidence will increase from 366 million in 2011 to 552 million by 2030. During the forecast period, the industry is expected to benefit from a significant increase in the number of diabetic patients. Furthermore, new product development is expected to benefit the market in the near future. For example, Novo Nordisk, a Danish pharmaceutical company, announced the launch of oral semaglutide for the treatment of Type 2 diabetes in India in January 2022. Furthermore, the development of advanced pumps based on smart technologies like AI and ML is expected to open up a slew of new doors. For exampl...

The global  Antidiabetics market  is estimated to secure US$ 223 Billion while expanding at a CAGR of 9.6% during the forecast period. The growth of the market can be attributed to the increasing prevalence of diabetes across the globe. Also, the aging baby boomer is another factor driving the market in the forecast period. According to International Diabetes Federation, the global diabetes incidence is anticipated to increase from 366 million in 2011 to 552 million by 2030. Such a significant increment in the number of diabetic patients is projected to benefit the industry in the forecast period. Also, the development of new products is anticipated to benefit the market in the coming time. . For instance, in January 2022, Novo Nordisk, the Danish drug provider, announced the launch of oral semaglutide in India for the treatment of Type 2 diabetes. Moreover, the development of advanced pumps based on smart technologies such as; AI and ML are predicted to offer various oppo...